Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer
02 Maio 2019 - 8:35AM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage
biopharmaceutical company focused on creating innovative cancer
immunotherapies, today announced that William Grossman, M.D., Ph.D.
has joined the Company as Chief Medical Officer. Dr. Grossman will
oversee all aspects of the Company’s global clinical development
strategy and operations.
“We are pleased to have Dr. Grossman join Arcus during this
seminal period in the advancement and expansion of our clinical
development programs,” said Terry Rosen, Ph.D., Chief Executive
Officer of Arcus. “Dr. Grossman has a distinguished background as a
practicing oncologist and has successfully led multiple global
cancer immunotherapy trials, from early-stage to commercialization.
He will complement the outstanding team that has already been
assembled and advanced Arcus’s first four product candidates into
clinical development. I look forward to having Bill as a colleague
and critical member of our senior leadership team as we move
towards later stage clinical trials.”
“I am honored to join Arcus at this pivotal time, with multiple
Phase 1 readouts in 2019,” commented Dr. Grossman. “Arcus’s
thoughtful strategy in leveraging promising biological targets,
potentially best-in-class molecules, comprehensive and unique
approach to clinical development and experienced team were key
reasons for joining the Company. I look forward to contributing to
the shared commitment of developing innovative cancer
immunotherapies for patients.”
Dr. Grossman has extensive experience leading successful global
clinical organizations, including direct medical accountability for
more than 50 clinical trials spanning Phase 1 through Phase 3. Dr.
Grossman joins Arcus from Bellicum Pharmaceuticals, where he served
as Chief Medical Officer and was responsible for the company’s
clinical development, regulatory affairs, clinical operations, and
medical affairs organizations. Prior to Bellicum, Dr. Grossman was
the Global Group Medical Director for Cancer Immunotherapy at
Genentech, where he led the clinical development of TECENTRIQ® in
gastrointestinal cancers and of cancer immunotherapy combinations
across all solid tumor types. Dr. Grossman designed and led the
Phase 1b/2 MORPHEUS platform, a rapid and efficient paradigm for
the evaluation of cancer immunotherapy combinations. Before joining
Genentech, Dr. Grossman led the development and execution of the
U.S. & Global medical affairs strategy for the oncology
franchise at AbbVie. Previously, he served as Senior Vice
President, Research & Clinical Development at Biothera, where
he oversaw all discovery and clinical development efforts in
oncology and immunology. In addition, Dr. Grossman has held
leadership positions in research, clinical development, and medical
affairs at Baxter Healthcare and Merck & Co., where he was
involved in the clinical evaluation of anti-cancer vaccines,
immunomodulatory agents, small molecules and biologics for
oncology.
Prior to joining the industry, Dr. Grossman held various
positions with the Children’s Hospital of Wisconsin/Medical College
of Wisconsin where he was Founder and Medical Director of the
Clinical Immunodiagnostic and Research Laboratory, Professor for
Microbiology and Genetics, and Director of the
Hematology/Oncology/Bone Marrow Transplant Division for the
Immunodeficiency Transplant Program. Dr. Grossman earned his M.D.
and Ph.D. (Immunology) degrees from Washington University School of
Medicine’s Medical Scientist Training Program and completed his
medical training in the Division of Pediatric Biology/Medicine at
the Washington University School of Medicine.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company
focused on creating innovative cancer immunotherapies. Arcus
has several programs targeting important immuno-oncology pathways,
including a dual adenosine receptor antagonist, AB928, which is in
a Phase 1/1b program to evaluate AB928 in combination with other
agents in multiple tumor types, and an anti-PD-1 antibody, AB122,
which is being evaluated in a Phase 1 trial and is being tested in
combination with Arcus’s other product candidates. Arcus’s other
programs include AB154, an anti-TIGIT antibody, which is being
evaluated in a Phase 1 trial as monotherapy and in combination with
AB122, and AB680, a small-molecule inhibitor of CD73, which is in a
Phase 1 healthy volunteer study. Arcus has extensive in-house
expertise in medicinal chemistry, immunology, biochemistry,
pharmacology and structural biology. For more information about
Arcus Biosciences, please visit www.arcusbio.com.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including, but not limited to, Arcus’s strategy and
expectations regarding the advancement and potential of its
clinical development programs, are forward-looking statements
reflecting the current beliefs and expectations of management made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All forward-looking statements
involve known and unknown risks, uncertainties and other important
factors that may cause Arcus’s actual results, performance or
achievements to differ significantly from those expressed or
implied. Factors that could cause or contribute to such differences
include, but are not limited to, the inherent uncertainty
associated with pharmaceutical product development and clinical
trials, the emergence of adverse events or other undesirable side
effects, delays in our clinical trials due to difficulties or
delays in the regulatory process, enrolling subjects or
manufacturing or supplying product for such clinical trials, and
changes in the competitive landscape for our programs. Risks and
uncertainties facing Arcus are described more fully in Arcus’s most
recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q
filed with the U.S. Securities and Exchange Commission. You are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date of this press release.
Arcus disclaims any obligation or undertaking to update, supplement
or revise any forward-looking statements contained in this press
release.
TECENTRIQ® is a registered trademark of Genentech, Inc.
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190502005277/en/
Katherine Bock(415) 533-5670kbock@arcusbio.com
Nicole Arndt(510) 284-4728narndt@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024